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From Rat Poison to Medicine: 
Medical Applications of Coumarin 
Derivatives
Robbert Bipat
Abstract
Historical reports mention the application of medicinal plants containing 
coumarins against various ailments. Current research suggests that at least some of 
the actions described may be attributable to the action of these coumarins. Warfarin 
and its derivatives are coumarins used today in medical practice. Their mechanism 
of action lies in the competitive antagonism of vitamin K, through which they 
inhibit coagulation in the body by preventing the production of prothrombin. Due 
to this action, these coumarins are a major group of drugs with anticoagulant activ-
ity. Anticoagulants reduce the risks of undesirable blood clots leading to myocardial 
infarction, pulmonary embolism, and ischemic stroke among others. The antico-
agulant activity can also lead to undesired bleeding. Extreme caution is warranted 
when given to menstruating women, patients suffering from disorders prone to 
bleeding like gastric ulcer and rheumatoid arthritis, and to persons with a high like-
lihood of blunt and sharp trauma. In addition, there is a significant augmentation 
of the anticoagulant activity when used in combination with non-steroidal anti-
inflammatory agents and agents interfering with the metabolism of the coumarins. 
Recent findings propose additional uses like anti-tumor and antibiotic actions for 
coumarins. The clinical application of these actions has yet to be demonstrated.
Keywords: warfarin, coumarin, anticoagulant, prothrombin, coagulation cascade, 
adverse reaction, rodenticide, embryopathy, vitamin K
1. Introduction
Coumarins are members of the benzopyrone class of organic compounds that 
are found in many plants [1] and possess a variety of pharmacological properties 
such as antimicrobial, anti-inflammatory, antidiabetic, and antioxidant activity, 
as well as a significant influence on physiological processes like enzyme inhibitory 
activity [2]. Despite the wide availability of coumarins and their lead compounds 
and metabolites in natural products [3], their application up till now has been 
mostly limited to the anticoagulant activity of warfarin derived from dicoumarol 
and its analogues [4]. The mechanism of action of these anticoagulants lies in the 
competitive antagonism of vitamin K, through which they inhibit coagulation of 
blood in the body by preventing the production of prothrombin and several other 
coagulation factors [5]. Due to this action, these coumarins are a major group of oral 
drugs with anticoagulant activity. Anticoagulants reduce the risks of undesirable 
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blood clots leading to myocardial infarction, pulmonary embolism, and ischemic 
stroke among others. This chapter gives an overview of medical applications of cou-
marins, in particular the history and evolution of warfarin and related compounds 
as important anticoagulant agents.
2. History
The medical application of plants containing coumarins probably started long 
before the isolation of this chemical compound from the Tonka bean in 1820 by 
Nicholas Jean Baptiste Gaston Guibourt [6]. Ancient Romans produced a cough 
syrup from the marshmallow (Althea officinalis) [7], which contains the coumarin 
scopoletin [8]. This coumarin demonstrated inhibition of leucocyte migration in 
mice [9], a process that can be linked to the alleged antitussive effect. Cough is 
a result of the reaction of the airways to leukotrienes and other factors secreted 
by leucocytes [10–12]. Inhibition of the migration of these to the affected region 
consequently reduces the availability of these paracrine factors. In addition, at least 
one of the herbs mentioned by the famous Roman General Pliny in his pharmaco-
peia [13] contain coumarins with proven action. For example, the extracts of the 
common rue or herb-of-grace Ruta graveolens contain xanthotoxin [14], a coumarin 
that reduces the mobility of human spermatozoa possibly through inhibition of 
membranaeous potassium channels [15].
The application of coumarin and its derivatives in current western medicine 
dates to the fifties of the past century with the clinical recognition of coumarins 
as anticoagulant agents. This event was the result of observations of poisoning of 
animals with coumarin derivatives that led to massive internal organ bleeding [16]. 
Soon it became clear that the substance that was responsible for the deadly internal 
bleeding of cattle was dicoumarol [17]. Shortly after this, the proposal was made 
to develop a coumarin derivative with rodent killing ability and gradually warfarin 
found its application as a potent rodenticide [18]. When it became clear that this 
substance also led to bleeding disorders after poisoning in human beings [19], its 
application as a therapeutic anticoagulant found its way in medicine [20, 21]. Seven 
decades later, warfarin is still in use as an anticoagulant [22]. In the meantime, 
several other coumarins with anticoagulant properties like acenocoumarol, phen-
procoumon, and fluindione have been developed, and they are used in a variety of 
clinical settings [23–25].
3. Physiology of hemostasis
Hemostasis in mammals and humans is the result of three sequential processes. 
The first of these is the acute vasoconstriction within seconds after damaged arter-
ies and veins, by local activity of the potent vasoconstrictor thromboxane among 
others [26]. The second step is the formation of a blood clot through the entrapment 
of platelets by fibrin within hours and finally followed by the organization of the 
fibrin mesh into an adhesive structure on the vessel wall [27]. In one of the last steps 
of the coagulation, prothrombin converts to thrombin, an enzyme that converts 
the plasma protein fibrinogen to fibrin monomers and activates factor XIII of the 
coagulation cascade. Activated factor XIII synthesizes fibrin from these monomers. 
The acquired fibrin molecules then trap the platelets and eventually form the blood 
clot [27, 28]. The coagulation process has both an intrinsic and an extrinsic pathway. 
The difference is that the intrinsic pathway only requires ionized calcium to be 
activated while the extrinsic pathway requires both calcium and tissue factor that 
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is released with trauma [28]. Figure 1 gives an overview of the coagulation process 
along with the interference sites of warfarin.
4. Pharmacology
4.1 Pharmacokinetics
Warfarin is highly lipid soluble [29–31]. Between 70 and 100% of the oral intake 
is rapidly absorbed by the intestines with a maximum plasma concentration within 
2 h after oral intake [30]. The half-life of the drug is generally more than 20 h, 
with a large individual variety [32]. Due to the overt lipid solubility, the major part 
of the drug is protein bound with less than 3% being biologically available [29]. 
Consequently, the agent has a slow onset of action and a long duration of activity 
[33]. In fact, the optimal effect is delayed for a few days, until all remaining acti-
vated factors II, VII, IX, and X are depleted from the liver and the circulation [33]. 
Warfarin accumulates in the liver where it exerts its effect and is inactivated through 
oxidative metabolism by cytochromes P450 to several isomers of water- soluble 
hydroxywarfarin with negligible anticoagulant activity [34, 35]. These metabolites 
are almost completely cleared by the kidneys [36]. The hepatic accumulation and 
relative easy absorption in the intestines result in an enterohepatic circulation of the 
drug [37]. Enterohepatic circulation is a process in which substances are secreted by 
the liver with bile to the intestines and subsequently absorbed again by the lat-
ter [28]. This results in recycling of the product with very little elimination.
4.2 Mechanism of action
Warfarin inhibits the enzyme vitamin K epoxide reductase that recycles oxi-
dized vitamin K [38]. Vitamin K activates the coagulating factors prothrombin 
Figure 1. 
Overview of the coagulation process along with the interference sites of warfarin.
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(factor II) and the structurally related serine proteases known as factors VII, IX, 
and X in the liver cells [27]. Decreasing the biological availability of vitamin K 
inhibits the synthesis of these essential factors and eventually leads to inhibition of 
the coagulation process. This means that this compound affects both the intrinsic as 
well as the extrinsic cascade of coagulation since prothrombin plays a central role in 
both of these pathways [28] and renders it a highly effective anticoagulant drug.
5. Indications and contraindications
Hemostasis is an essential process to prevent significant external as well as 
internal blood loss after injury. However, under certain circumstances, it is not 
desirable to activate or continue this homeostatic process like in disorders with 
spontaneous thrombosis such as deep venous thrombosis in the legs often resulting 
in pulmonary embolism [39]. In addition, there are conditions that are prone to a 
reasonable chance of forming a blood clot during stasis of the blood circulation like 
in atrial fibrillation and in the limbs of patients with prolonged immobility after 
surgery [39]. Moreover, conditions like myocardial infarction or ischemic stroke 
form a preventable group of disorders with inhibition of the thrombotic process [5]. 
Based on its anticoagulant properties, warfarin is thus an ideal compound for the 
treatment and prevention of these thromboembolic conditions [5].
Based on the pharmacokinetic properties and the challenges they present, 
dosing of warfarin is not simple, and a careful approach is necessary. On one hand, 
a low plasma concentration will not achieve the effect of sufficient anticoagulation 
and, on the other side of the spectrum, there is the constant chance of overdosing 
with potential lethal internal or external bleeding. Another problem is the great 
variety of absorption, body distribution, and metabolism of the agent with indi-
vidual patients based on the pharmacokinetic properties of warfarin [30]. Frequent 
monitoring of therapeutic efficiency with adequate laboratory tools like prothrom-
bin time (PT) or international normalized ratio (INR) is absolutely necessary [40, 
41] and a fixed or constant dose is close to impossible. Nevertheless, warfarin is 
highly effective in anticoagulation regiments when carefully dosing and assess-
ing the potential bleeding sites as well as other potential side effects. Warfarin is 
initially dosed at 5–10 mg daily [42]. Subsequent doses depend on the international 
normalized ratio, with a therapeutic value between 2 and 4. Concomitant adminis-
tration of heparins like fraxiparine is necessary when fast anticoagulant activity is 
desirable [43].
Warfarin is not an ideal agent in conditions when immediate treatment of 
thromboembolism is imminent due to the long time of onset. In cases of pulmo-
nary embolism and acute ischemic stroke, it is desirable to start with both the oral 
anticoagulant and fast-acting agent like heparins [44]. The long duration of action 
harbors another challenge. When acute termination of anticoagulation is necessary 
with unwanted bleeding like in menstruating women and after blunt and sharp 
trauma leading to hemorrhage, it could take days before the process of coagulation 
completely restores after quitting oral administration [27, 30] due to the depletion 
of coagulant factors in liver and blood. In these cases, intravenous administration of 
prothrombin complex, fresh frozen plasma with coagulation factors, and high doses 
of vitamin K may be helpful [45].
Warfarin readily passes the placenta and may result in spontaneous abortion 
due to retroplacental bleeding [46], as well as prematurity [47], fetal deformity 
[48], stillbirth [48], and fetal cranial bleeding [49]. Administration during the first 
trimester of pregnancy has a high risk of embryopathy [50]. This is accompanied 
by deformities of bone and cartilage [51], blindness, mental retardation, and other 
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neurologic abnormalities [52]. The occurrence of these complications and defects 
seem to be dose dependent [47, 53] and are most probably the result of the interfer-
ence with vitamin K-dependent coagulation [38] and bone formation [54]. The 
effects of the central nervous system and the blindness are probably the result of 
microhemorrhages in the developing brain as a result of the anticoagulant activ-
ity [55]. Clotting factors are easily depleted in the fetus due to the immature liver 
and small circulating volume [46]. Warfarin does not enter breastmilk and is thus 
completely safe during lactation [56].
In conclusion, warfarin must be administered with great caution to women in 
their child-bearing age [57]. Therapy with this agent must be ceased immediately 
when it becomes clear that the patient is pregnant. Low-molecular weight heparins 
are a good alternative, since they do not cross the placenta and have been proven to 
be safe for mother, embryo, and fetus [58].
6. Drawbacks and side-effects
To say that anticoagulant coumarins have only a few side effects is an absolute 
understatement. Warfarin is one of the leading drugs with adverse effects requiring 
hospital admission [59]. Most of all, there is the constant chance of severe bleeding 
[60]. This can include internal hemorrhagic conditions in the head, gastrointestinal 
tract, female genitalia, the bladder and urethra or skeletal joints and muscles [40, 61]. 
They generally present as severe headache, stomach pain, and black or bloody stool, 
heavier than normal menstrual bleeding, discoloration of urine, and pain and swell-
ing of the joints or muscles. Prolonged bleeding from external sharp or blunt wounds 
is always present [61]. All these conditions are the result of inability of the affected 
tissues to initiate and continue the process of hemostasis after damage to the epithelial 
barrier [62].
Patients suffering from hypertension, disorders of the liver, bleeding lesions, 
and the elderly and patients using drugs and substances that affect coagulation 
are at higher risk to suffer from bleeding when using warfarin [63]. Hypertension 
poses mechanical defects in the blood vessels, especially the arteries. Disorders 
of the liver reduce the ability of the body to eliminate the warfarin and thus make 
it more biologically available. In bleeding lesions, warfarin inhibits hemostasis. 
Among substances that can lead to bleeding when used with warfarin are steroidal 
and non-steroidal anti-inflammatory drugs, antibiotics, and alcohol. These potenti-
ate the activity, interfere with the protein binding, and reduce the metabolism of 
warfarin, respectively [63]. Other side effects include injury to the kidneys with 
potential nephritis [64–66], inflammation of the skin [67] and blood vessels [66], 
and potentiation of rhabdomyolysis by simvastatin [64].
Due to resistance of rodents against warfarin, superwarfarins have been created 
[68]. These have a much longer time of activity and hence need only to be con-
sumed once by the rodents, contrary to warfarin. The result however is that their 
effect persists much longer when deliberately or accidently consumed by humans 
[69] and treatment of this intoxication is a more challenging enterprise.
7. Interaction with drugs and foods
The efficacy of the anticoagulant treatment with warfarin highly depends on its 
bioavailability, since inhibition of the target (epoxy reductase) enzyme depends on 
direct binding of the drug to this protein [38]. In addition, vitamin K from external 
sources does not rely on recycling through this enzyme [38]. Hence, the absorption, 
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Agent Category Possible 
mechanism
Effect Reference
Allopathic 
medications
Amiodarone Antiarrhythmic Inhibition 
of hepatic 
metabolism
[78]
Ciprofloxacin Antibiotic Reduction 
of vitamin 
K synthesis 
by intestinal 
bacteria
Increased 
bleeding
[79]
Paroxetine Antidepressant Inhibition 
of hepatic 
metabolism
Potentiation [80]
Citalopram Antidepressant Inhibition 
of hepatic 
metabolism
Potentiation [80]
Clopidogrel Antiplatelet 
medication
Inhibition 
of 
coagulation 
cascade
Potentiation [81]
Dipyridamole Antiplatelet 
medication
Inhibition 
of 
coagulation 
cascade
Potentiation [81]
Diclofenac NSAID Inhibition 
of 
coagulation 
cascade
Potentiation [82]
Naproxen NSAID Inhibition 
of 
coagulation 
cascade
Potentiation [82]
Acetaminophen Analgesic Interference 
with hepatic 
metabolism
Increased 
bleeding
[83]
Food 
supplements
Fish oil Lipid profile 
improvement
Inhibition 
of 
coagulation 
cascade?
Potentiation [84]
Pomegranate 
juice
Antioxidant Interference 
with hepatic 
metabolism
Potentiation [85]
Glucosamine Cartilage 
improvement
Unknown Potentiation [86]
Traditional 
medications
Chamomile Medicinal 
herbal tea
Unknown Increased 
bleeding
[87]
Ginseng Improving 
cognitive 
functions
Unknown Inhibition [88]
St John’s wort Against 
depression
Induction 
of 
metabolism
Inhibition [89]
Table 1. 
Brief overview of possible interactions with warfarin.
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transport, delivery, and elimination of warfarin as well as the external availability 
of vitamin K are potential sites of interaction with other drugs and with food and 
dietary supplements.
Drugs and food that influence the enterohepatic circulation can all affect the 
absorption of warfarin. Examples of these are the drug cholestyramine [37] and 
the avocado fruit [70], which prevent the reabsorption of warfarin in the intestines 
Concomitant administration of other protein-bound drugs may lead to greater 
amounts of circulating warfarin and increased risks of bleeding. Valproate sodium 
increases the bioavailability of warfarin through dislocation of its protein-binding 
sites [71]. Interference with the metabolism of warfarin is a potential of most drugs 
that are eliminated by hepatic metabolism. Among these are aspirin [72], non-
steroidal anti-inflammatory drugs [72], serotonin reuptake inhibitors [49], anti-
platelet agents and some antibiotics [72]. It can go both ways with the metabolism. 
Induction of the cytochromes will increase the elimination, while occupation of the 
binding sites by the drugs will increase the availability of warfarin.
Since warfarin acts through elimination of available bioactive vitamin K, varia-
tions of the net intake of this vitamin will certainly interfere with the drug action. 
A high intake of the vitamin will keep the coagulant factors at a higher level and 
thus inhibit the anticoagulant activity. Likewise, a lower intake will potentiate the 
effect of warfarin. The vitamin occurs in food in the form of phylloquinone and 
menaquinone. Phylloquinone is the form mostly found in plants and is also the most 
abundant form in food [73]. Menaquinones are mainly the product of bacterial pro-
duction or conversion [74]. Consequently, simple multivitamin and other supple-
ments, food with high vitamin K content [74] as well as antibiotics are sources of 
fluctuation in vitamin K intake since intestinal bacteria significantly contribute to 
the production of menaquinones [75].
Recently, another source of interference came into focus. In addition to the previ-
ous mentioned parameters, genetic variation in the expression of cytochrome P450 
seems to play a role in the metabolism of warfarin [76], thus influencing the availabil-
ity of the drug [77]. All these considerations make it clear that close monitoring of the 
individual coagulation ability is necessary for a successful therapy with this agent.
The abovementioned interactions are just a few of the many that are possible. 
Table 1 gives examples of a variety of interactions with drugs, food, natural prod-
ucts, and supplements. This is only to underscore the cautious approach patients 
should practice when taking warfarin.
8. Future prospects and conclusion
Today, coumarins find their application predominantly as anticoagulants in 
medicine. The narrow therapeutic index of warfarin and related compounds 
sometimes limit their applicability and consequently there is a constant search for 
more safe agents in this drug class [90]. Unfortunately, the development of these 
will probably limit the use of these oral anticoagulants.
Aside from these developments, coumarins with several applications in medical 
practice are progressively being introduced. Investigators found that coumarin-
3-carboxylic acid could be utilized as a dosimeter for radiotherapy. This substance 
converts to the highly fluorescent 7-hydroxy-coumarin-3-carboxylic acid, with a 
near perfect linear correlation upon irradiation [91].
The coumarin 2-hydroxycinnamic acid demonstrated inhibitive properties on 
the enzyme carbonic anhydrase [92]. Inhibition of this enzyme leads to diuresis [93] 
and decreases intraocular pressure in glaucoma patients [93] with clear therapeutic 
potential and clinical perspective.
Phytochemicals in Human Health
8
Furano(pyrano)coumarins found in the roots of the Korean angelica (Angelica 
gigas) showed antibacterial activity in hay bacillus (Bacillus subtilis) cultures [94]. 
The coumarine derivative cloricromene reduced the inflammatory parameters in 
rats subjected to collagen-induced arthritis [95]. In addition, several studies found 
that coumarins may be useful as anti-tumor agents [4, 96].
Probably since ancient times, coumarins found their application in medicine. 
Currently, however, coumarins with predominantly anticoagulant properties 
are applied in daily medical practice. These have been developed from the initial 
discovery of a cattle killing weed more than six decades ago. Initially applied as 
a rodenticide, soon a therapeutic usable oral anticoagulant was developed, and 
slowly other agents entered the market. They have a small therapeutic index, 
rendering them toxic in a number of circumstances. The search for more safe agents 
with anticoagulant effects is ongoing and this may result in a decline of the use of 
coumarins in this field. Nevertheless, coumarins gradually find their way in other 
fields of medicine. Nevertheless, all these developments promise a bright future for 
coumarins in medical applications.
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